RE: MASSIVE NEWS28 Aug 2020 10:44
In response to the COVID-19 pandemic, Beximco Pharma has taken various proactive measures to provide the latest, evidence-based treatment options for COVID-19 patients. The Company is committed to fighting this pandemic, in all possible ways,employing its competitive R&D and manufacturing skills. Beximco Pharma has already launched the anti-viral drug favipiravir(under the brand name Viraflu), as well as the repurposed antimalarial drug hydroxychlorquine (under the brand name Kovicin) andanti-parasitic drug ivermectin (under the brand name Ivera) as potential treatments for COVID-19.